Please try another search
For the three months ended 31 March 2022, Dongsung Pharmaceutical Co Ltd revenues increased less than 1% to W22.41B. Net loss increased from W712.9M to W1.44B. Revenues reflect Cosmetics/Toilet Preparation Segment increase of 63% to W1.6B, Oversea segment increase of 20% to W2.23B, also reflect Pharmaceutical Segment decrease of 2% to W20.81B, South Korea segment decrease of 1% to W20.18B.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 22412.52 | 20813.06 | 18324.13 | 22959.91 |
Gross Profit | 9918.32 | 7213.57 | 8408.37 | 9462.93 |
Operating Income | -1667.67 | -2720.22 | -987.84 | -302.38 |
Net Income | -1435.58 | -2969.69 | -518.66 | -111.63 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 109065.64 | 104581.87 | 111428.19 | 107827.93 |
Total Liabilities | 64304.24 | 58141.48 | 60834.71 | 54544.4 |
Total Equity | 44761.4 | 46440.39 | 50593.48 | 53283.53 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -525.44 | -2751.53 | -1741.43 | -698.16 |
Cash From Investing Activities | -442.61 | -9699.76 | -6937.6 | -9156.16 |
Cash From Financing Activities | 3558.53 | 1231.79 | 3925.87 | -2220.16 |
Net Change in Cash | 2591.49 | -11211.94 | -4711.2 | -12069.03 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review